Nutlin-3 enhances sorafenib efficacy in renal cell carcinoma - Wikidata - wikimedia - TriplyDB

Nutlin-3 enhances sorafenib efficacy in renal cell carcinoma

Nutlin-3 enhances sorafenib efficacy in renal cell carcinoma

http://www.wikidata.org/entity/Q34127380

about

Nutlin-3a: A Potential Therapeutic Opportunity for TP53 Wild-Type Ovarian Carcinomas A novel combination therapy approach for the treatment of acute myeloid leukemia: the multi-kinase inhibitor sorafenib and the HDM2 inhibitor nutlin-3 The sorafenib plus nutlin-3 combination promotes synergistic cytotoxicity in acute myeloid leukemic cells irrespectively of FLT3 and p53 status The MDM2 small-molecule inhibitor RG7388 leads to potent tumor inhibition in p53 wild-type neuroblastoma The MDM2-p53 pathway revisited TRIM8 restores p53 tumour suppressor function by blunting N-MYC activity in chemo-resistant tumours.Targeting p53-MDM2-MDMX loop for cancer therapy.Cell death-based treatment of neuroblastoma.Epigenetic silencing of ASPP1 confers 5-FU resistance in clear cell renal cell carcinoma by preventing p53 activation.

P2860

Q28547093-FB049775-1EEA-47B9-96D7-27082D134A9D Q36366552-FD49CE3E-2FB0-4CD1-BA4D-39EB2C2E82A8 Q36366626-17162FC4-E538-478E-81CF-F0CFFDBA1DE4 Q36692848-F1ABA346-99C4-47B3-B83E-C1CC65B43B55 Q37039474-5EA8EE7F-78EB-4CE2-BADE-437502BAC073 Q37713334-CF970C66-658C-48CC-A152-6F77CEC23B5F Q38247168-585DF547-E783-482E-9A42-12BDA164C1EC Q47839039-8E63ADBA-64FC-4E2C-8CB0-387DFB7985B9 Q47979679-E3C5EA74-8FD6-4B82-9DD2-77BF91CF1D99

P2860

Nutlin-3 enhances sorafenib efficacy in renal cell carcinoma

http://www.wikidata.org/entity/Q34127380

description

2011 nî lūn-bûn

@nan

2011 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

name

Nutlin-3 enhances sorafenib efficacy in renal cell carcinoma

@ast

Nutlin-3 enhances sorafenib efficacy in renal cell carcinoma

@en

Nutlin-3 enhances sorafenib efficacy in renal cell carcinoma

@nl

type

label

Nutlin-3 enhances sorafenib efficacy in renal cell carcinoma

@ast

Nutlin-3 enhances sorafenib efficacy in renal cell carcinoma

@en

Nutlin-3 enhances sorafenib efficacy in renal cell carcinoma

@nl

prefLabel

Nutlin-3 enhances sorafenib efficacy in renal cell carcinoma

@ast

Nutlin-3 enhances sorafenib efficacy in renal cell carcinoma

@en

Nutlin-3 enhances sorafenib efficacy in renal cell carcinoma

@nl

P1433

Q34127380-E568ED75-D181-401F-917E-02880DB6B5A0

P1476

Q34127380-DDEA3852-779F-4639-BFA3-BD7A2A42E7EC

P2093

Q34127380-6C08F424-877E-49A6-A700-10C3CEDBA09D

Q34127380-75A6F50E-9F0D-48F2-92EF-556E6A0F6F36

Q34127380-CE1A1E5E-5976-439A-B31A-1CD3D7075F8A

Q34127380-D763724C-A040-45A3-86AD-4311D1426BE4

Q34127380-DC43AC81-6A72-480E-A53E-7B6C85F6A062

P2860

Q34127380-02DD1802-2B08-4771-9F00-D0A70B483190

Q34127380-24B8D21E-43BC-4434-BF4A-D00EE017B1F2

Q34127380-2F37B2DD-BB4F-4230-BE11-0D6DC20AC447

Q34127380-2F899585-B52B-4D78-8A9A-82A568660F57

Q34127380-35586DC1-9864-4950-B309-0BC70C13E80D

Q34127380-41701875-B497-4FA4-B39D-18C898EC1D70

Q34127380-48A8ABF9-2369-4614-BB33-C24F65667F8C

Q34127380-4A333192-B102-4E0F-94D7-7F51EF70A218

Q34127380-4AE6E4D8-F946-404A-884D-B3520A7B3479

Q34127380-5290C751-B36F-4BE7-B121-33AA7D6217E7

P304

Q34127380-405C1693-E6D2-4DDD-87D4-BAE864C9F9EF

P31

Q34127380-9C8D080C-19D8-4472-B89F-99198AA39537

P356

Q34127380-F9B839A5-21B4-4FBD-AD27-9297E29ED3D6

P433

Q34127380-AE8DAF87-A75D-417B-AABD-58078D6A6E5D

P478

Q34127380-D4BCB29B-4780-4E3F-931B-9D2ED3A3EFF1

P577

Q34127380-67BBBD9F-C21B-4906-9CDA-BA8B06B26453

P5875

Q34127380-2B1C987B-117C-4288-A18B-8CA7AF478D47

P698

Q34127380-A89D893C-2E6C-4449-B20D-85ACF56B6FC0

P932

Q34127380-F6B469B1-50DD-4147-B7C6-01680ECB0DA4

P356

P1433

Molecular Carcinogenesis

P1476

Nutlin-3 enhances sorafenib efficacy in renal cell carcinoma

@en

P2093

Jyotsana Singhal

http://www.w3.org/2001/XMLSchema#string

Lokesh Dalasanur Nagaprashantha

http://www.w3.org/2001/XMLSchema#string

Rit Vatsyayan

http://www.w3.org/2001/XMLSchema#string

Sanjay Awasthi

http://www.w3.org/2001/XMLSchema#string

Sharad S Singhal

http://www.w3.org/2001/XMLSchema#string

P2860

PUMA couples the nuclear and cytoplasmic proapoptotic function of p53

Mdm2 promotes the rapid degradation of p53

Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy

Sorafenib in advanced hepatocellular carcinoma

Sorafenib in advanced clear-cell renal-cell carcinoma

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

Tumor suppressor p53 is a direct transcriptional activator of the human bax gene

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

P304

39-48

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/MC.20875

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

52

http://www.w3.org/2001/XMLSchema#string

P577

2011-10-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51726196

http://www.w3.org/2001/XMLSchema#string

P698

22006587

http://www.w3.org/2001/XMLSchema#string

P932

4153352

http://www.w3.org/2001/XMLSchema#string